The Case for Decriminalising Ibogaine in the US
The conversation around psychedelics is evolving, and the recent Joe Rogan podcast has reignited the case for decriminalising ibogaine in the US, along with its immense potential for healing. At Tabula Rasa Retreat, we’ve long advocated for reform and responsible regulation of ibogaine. Even though ibogaine is technically an oneirogen—a substance that induces a dream-like state—classic psychedelics like ayahuasca, psilocybin, and 5-MeO-DMT also have profound medicinal and therapeutic value. Their demonization under outdated legislation does a disservice to those seeking transformative healing.
To understand the legislative dismissal of psychedelic therapy, we need to rewind a few decades in U.S. politics to the Nixon administration (1969–1974) and examine its connection to American foreign policy—particularly the Vietnam War—and the counterculture’s response to that policy.
Nixon’s War on Drugs: A Policy of Control and Suppression
In the recent Joe Rogan podcast, a critical light is shone on the War on Drugs, which was initiated by President Richard Nixon in 1971. Rogan references how this campaign was less about public health and more about political control. Nixon’s designation of substances like ibogaine and psychedelics as Schedule I drugs—claiming they had “no medicinal value” and a high potential for abuse—was not grounded in any form of scientific evidence; instead, it was a calculated move to suppress political dissent, marginalised communities and the growing anti-establishment counterculture of the 1960s.
As Rogan discusses, Nixon’s own aides, including John Ehrlichman, later admitted that the administration used drug policy as a tool to target the anti-war left and Black communities. Ehrlichman stated in a 1994 interview:
“We knew we couldn’t make it illegal to be either against the war or Black, but by getting the public to associate the hippies with marijuana and the Blacks with heroin, and then criminalising both heavily, we could disrupt those communities.”
This shocking admission reveals the War on Drugs as a cynical strategy to consolidate power, not to address substance misuse or public safety.
Psychedelics, including LSD, psilocybin, and ibogaine, were also classified as Schedule I substances in the United States with the passage of the Controlled Substances Act (CSA) in 1970 during Richard Nixon’s presidency, a legislation which effectively halted scientific research and therapeutic applications that had been developing since the mid-20th century.
Prior to this sweeping prohibition, the scientific community had uncovered significant therapeutic applications for psychedelics. LSD was studied extensively in the 1950s and 1960s as a treatment for mental health conditions such as depression, anxiety, and addiction, particularly alcoholism. Researchers like Dr. Humphry Osmond and Dr. Sidney Cohen found that psychedelics could facilitate profound psychological breakthroughs, offering patients relief from entrenched patterns of thought and behaviour. Similarly, psilocybin showed promise in reducing existential anxiety in terminally ill patients and improving mood disorders.
Ibogaine, discovered in the early 20th century for its psychoactive properties, was studied in the 1960s as a potential treatment for opioid addiction. Research by Howard Lotsof revealed its ability to mitigate withdrawal symptoms and cravings while offering profound insights into the root causes of addiction. Unlike other psychedelics, ibogaine’s mechanism of action appeared uniquely suited to addressing the physiological and psychological facets of substance dependency. Yet, despite this promising evidence, ibogaine was swept into the same prohibitive legislation as other psychedelics, halting its development as a medical treatment.
The move to Schedule I classification ignored this growing body of evidence and prioritised political concerns over public health. Psychedelics and ibogaine became casualties of the broader “War on Drugs,” a policy shaped more by cultural and ideological battles than by scientific reasoning. This decision not only criminalised substances with immense therapeutic potential but also silenced decades of promising research, the effects of which continue to reverberate in the current discourse on drug policy reform.
A Legacy of Harm and Distrust
Nixon’s policies set the stage for decades of mass incarceration, disproportionately affecting minorities and exacerbating social inequalities. The demonisation of psychedelics, including ibogaine, was part of this broader effort to suppress movements advocating for civil rights, personal freedom, and a departure from the establishment’s norms. Psychedelics were associated with the counterculture and perceived as a threat to the status quo because they encouraged introspection, community, and questioning of authority.
This legacy endures, creating immense barriers to the therapeutic use of psychedelics and perpetuating mistrust between communities and institutions. As advocates for decriminalising ibogaine, Tabula Rasa Retreat believes that it is time to dismantle these oppressive structures and embrace evidence-based, compassionate approaches to substance use and mental health. Psychedelics are not a threat; they are a tool for healing and transformation that has been unjustly buried under decades of political machinations.
The Broader Demonization of Psychedelics
Ibogaine is not alone in facing unwarranted stigma. Substances like ayahuasca, psilocybin, and 5-MeO-DMT—all deeply rooted in indigenous traditions—are similarly demonized. These compounds are essential tools in addressing trauma, fostering self-awareness, and unlocking human potential.
• Ayahuasca, used for centuries in Amazonian cultures, helps individuals confront past traumas and release emotional blockages.
• Psilocybin, derived from “magic mushrooms,” is now recognized for its potential to treat depression and anxiety.
• 5-MeO-DMT, known as the “God molecule,” facilitates profound spiritual experiences and emotional breakthroughs, and in conjunction with ibogaine, is key in healing from PTSD.
Now, more than ever, decriminalising ibogaine matters deeply, not only because of the amount of US war veterans suffering from PTSD, but also because of the country’s burgeoning opioid crisis, which shows no sign of stopping anytime soon.
America’s Shifting Landscape: A Glimmer of Hope
However, as evidenced by Governor Rick Perry on Rogan’s podcast, the tide may well be ready to turn. Several U.S. states, including Oregon and Colorado, have decriminalized certain psychedelics, recognizing their therapeutic potential. Even conservative political factions, such as some elements of the current Republican administration, historically resistant to drug policy reform, are showing signs of openness. As Rogan pointed out, “There’s an anti-establishment current even in Republican circles right now. It’s not impossible to imagine change coming from both sides of the aisle.”
The Role of Tabula Rasa Retreat in the Decriminalisation of Ibogaine
At Tabula Rasa Retreat, we’ve been at the forefront of advocating for psychedelic-assisted therapies in Portugal, where drug decriminalization has already proven effective.
Even though ibogaine enjoys an unregulated status in Portugal, our ongoing work with Portugal’s drug reform agencies to have it regulated for clinical use underscores our commitment to integrating not only ibogaine but also psychedelics in general into regulated therapeutic frameworks.
Here at our treatment centre in Portugal, we have seen first hand how ibogaine has helped our clients heal from both behavioural addictions and substance addictions, depression, anhedonia, and PTSD.
Additionally, our other centre in Mexico, Genesis Parkinson’s Institute, is also exploring ibogaine’s neuroregenerative properties, offering hope for conditions like Parkinson’s and Multiple Sclerosis. This is a global fight, and we remain steadfast in our mission to educate, advocate, and provide safe spaces for transformative healing.
